国药现代：法莫替丁注射液通过仿制药一致性评价

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the approval of Famotidine injection by the National Medical Products Administration signifies a significant advancement in the company's product portfolio and its ability to meet market demands for gastrointestinal treatments [1] Group 1 - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received the approval notice for the supplementary application of Famotidine injection [1] - Famotidine is classified as a histamine H2 receptor antagonist, primarily used for treating upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor-related conditions [1] - The approval indicates that Famotidine injection has passed the consistency evaluation of generic drug quality and efficacy, enhancing its market competitiveness [1]